Outlook Therapeutics, Inc. 8-K

What Happened
Outlook Therapeutics, Inc. (OTLK) reported on June 1, 2026, via a Form 8-K that it has resubmitted the Biologics License Application (BLA) for ONS-5010 to the U.S. Food and Drug Administration (FDA). The company attached a press release announcing the resubmission as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: Form 8-K filed and press release issued on June 1, 2026.
• Action: Resubmission of the BLA for ONS-5010 to the FDA.
• Disclosure: Press release is included as Exhibit 99.1 to the Current Report on Form 8-K.
• Reported under Item 8.01 (Other Events) of Form 8-K.

Why It Matters
A BLA resubmission is a material regulatory development: it advances the company’s ongoing interactions with the FDA and is a step in the process toward potential regulatory approval of ONS-5010. For investors, this is a regulatory milestone to monitor—watch for subsequent FDA communications, approval timelines, and future company updates that could affect Outlook Therapeutics’ clinical and commercial prospects.